A Phase 2, Open-Label, Single-Arm, Sequential-Panel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Posaconazole (POS, MK-5592) in Pediatric Participants From Birth to <2 Years of Age with Invasive Fungal Infection

Administered By

Awarded By

Contributors

Start/End

  • September 30, 2020 - June 30, 2025